Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

Rhea-AI Summary

Revvity (NYSE: RVTY) has expanded its partnership with Genomics England for the Generation Study, adding DNA sequencing services to their existing DNA extraction services. The collaboration aims to screen up to 100,000 newborns for over 200 rare genetic disorders through whole genome sequencing (WGS).

The company will provide an integrated end-to-end solution with a localized lab facility, enabling faster extraction and sequencing services. This research project, conducted in partnership with the National Health Service, will help inform future decisions on implementing WGS in newborn screening programs, potentially enabling earlier interventions and personalized care for pediatric-onset conditions.

Positive

• Expanded service offering through addition of DNA sequencing services
• Large-scale project covering 100,000 newborns
• Integrated end-to-end solution with localized lab facility
• Strategic partnership with national healthcare institutions

Negative

• None.

Insights

Healthcare Technology Analyst

Revvity's expanded partnership with Genomics England represents a strategic strengthening of their position in the growing genomic sequencing market. By adding sequencing services to their existing extraction services, they've effectively created an integrated end-to-end solution that captures more value in the workflow and increases their competitive advantage.

The Generation Study's scale is significant - screening up to 100,000 newborns for over 200 rare genetic disorders - positioning this as a substantial commercial opportunity. While financial terms weren't disclosed, this expanded service offering should drive incremental revenue growth and further embed Revvity within the UK's healthcare infrastructure.

The localized lab facility mentioned is particularly noteworthy as it creates operational efficiencies that enable faster turnaround times - a critical factor for newborn screening where time directly impacts treatment efficacy. This capability could serve as a differentiator for winning similar contracts globally.

The strategic implications extend beyond this specific contract. As governments worldwide consider implementing genomic sequencing for newborn screening, Revvity is positioning itself as an experienced partner with proven capabilities in a national-scale implementation. This reference project could catalyze additional business opportunities as other healthcare systems follow the UK's lead.

Business Development Specialist

This expanded agreement represents a classic land-and-expand business development strategy executed effectively. Revvity has successfully leveraged their initial extraction services contract to secure additional sequencing work, capturing more of the value chain within this prestigious national project.

From a commercial perspective, the integration of these services creates meaningful competitive barriers. By providing both extraction and sequencing with a localized facility, Revvity establishes operational synergies that would be difficult for competitors to replicate without significant investment. This integrated approach likely improves margins while delivering enhanced value to Genomics England.

The Generation Study itself has significant commercial implications. As a research initiative that could inform future national healthcare policy, successful execution could position Revvity for much larger implementation contracts if whole genome sequencing becomes standard practice in newborn screening. The current work essentially serves as a paid proof-of-concept for potentially much larger future opportunities.

While specifics around contract value remain undisclosed, the strategic positioning is undeniably positive. By establishing themselves as a trusted partner capable of delivering end-to-end genomic solutions for a sensitive application like newborn screening, Revvity is building valuable credibility that will likely translate to business development advantages across their broader portfolio.

New agreement to support newborn health adds sequencing lab services to the existing extraction services collaboration

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY) today announced an agreement with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions. This expanded relationship builds upon the previously disclosed agreement to perform DNA extraction services. Revvity will now be able to provide an integrated end-to-end solution with a localized lab facility, which will allow for accelerated extraction and sequencing services to advance the screening process for these rare conditions.

The Generation Study, a research project spearheaded by Genomics England in partnership with the National Health Service, is a landmark national initiative aimed at screening up to 100,000 newborns for more than 200 rare genetic disorders. The findings will help inform future decisions on using whole genome sequencing (WGS) in newborn screening. Proactive genomic screening could help healthcare professionals identify risks for pediatric-onset conditions sooner, enabling earlier interventions and personalized care.

“It is an honor to enhance our collaboration with Genomics England as we align to expand access to genomic sequencing in England. Our complete solution and localized lab facility help us deliver timely and reliable sequencing data in support of this critical program that strengthens newborn health,” stated Dr. Madhuri Hegde, Revvity’s senior vice president and chief scientific officer. “Revvity’s expansive global laboratory network combined with our next-generation sequencing solutions and workflows for newborn screening uniquely positions us to lead this and similar initiatives, setting a standard for future programs.”

“This collaboration is an important step forward in our mission to generate evidence on the use of genomic sequencing in newborn screening. By working with Revvity as one of our sequencing partners for the Generation Study, we can integrate sequencing alongside extraction, streamlining the process, and generating results more efficiently, helping families get answers and access to care sooner,” said Dr. Ellen Thomas, chief medical officer at Genomics England.

To learn more about Revvity’s newborn sequencing research solutions, please visit: https://www.revvity.com/category/newborn-sequencing-research

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

About Genomics England

Genomics England is a global leader in enabling genomic medicine and research, established by the United Kingdom's Department of Health and Social Care, focused on creating a world where everyone benefits from genomic healthcare. Building on the 100,000 Genomes Project, it supports the NHS’s world-first national whole genome sequencing service and runs the growing National Genomic Research Library, alongside delivering numerous major genomics initiatives including the Generation Study. By connecting research and clinical care at national scale, it enables immediate healthcare benefits and advances for the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250320502295/en/

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Revvity Media Relations:

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Genomics England Media:

media@genomicsengland.co.uk

Source: Revvity

FAQ

What is the scope of Revvity's (RVTY) expanded partnership with Genomics England?

Revvity will now provide both DNA sequencing and extraction services for the Generation Study, offering an integrated end-to-end solution with a local lab facility to screen newborns for rare genetic conditions.

How many newborns will be screened in the Generation Study involving RVTY?

The study aims to screen up to 100,000 newborns for more than 200 rare genetic disorders.

What is the potential impact of Revvity's (RVTY) involvement in the Generation Study?

The study will help inform decisions on using whole genome sequencing in newborn screening, potentially enabling earlier detection and intervention for pediatric-onset conditions.

How will RVTY's local lab facility benefit the Generation Study?

The localized lab facility will accelerate extraction and sequencing services, streamlining the process and helping families get answers and access to care sooner.